Amphivena Therapeutics' Series A Round

Amphivena Therapeutics raised a round of funding on July 15, 2013.

Amphivena Therapeutics, in collaboration with Affimed, develops bispecific TandAbs for hematologic malignancies. TandAbs are tetravalent bispecific antibody formats that have two binding sites for eac…

Articles about Amphivena Therapeutics' Series A Round: